

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

8' 1. (Currently Amended) A multi-phase combination preparation comprising a predetermined ordered daily sequence of at least 28 individual daily dosage units comprising for administration to a patient, wherein the predetermined ordered daily sequence comprises

a first phase of at least 21 initial dosage units to be administered daily to said patient according to said predetermined order, each individual dosage unit comprising a competitive progesterone antagonist in an effective amount to inhibit ovulation during the first phase, and followed in the ordered sequence by

a second phase of 5 to 28 daily separate dosage units to be administered daily to said patient, wherein each dosage unit of this the second phase comprising comprises a gestagen, wherein the daily dosage units are to be taken daily by a user in the ordered sequence such that the daily units of progesterone antagonist are taken initially followed by separate administration of the daily dosage units of gestagen.

2. (Original) A multi-phase combination preparation of claim 1, wherein the first phase comprises 21 to 27 initial daily dosage units.

3. (Original) A multi-phase combination preparation of claim 1, wherein the first phase comprises at least 28 and at most 77 initial daily dosage units.

4. (Original) A multi-phase combination preparation of claim 1, wherein the first phase comprises 28 initial daily dosage units.

5. (Previously Amended) A multi-phase combination preparation of claim 1, wherein the second phase comprises 7 to 14 daily dosage units.

6. (Original) A multi-phase combination preparation of claim 1, wherein the first phase comprises 21 initial daily dosage units and a second phase comprises 7 daily dosage units.

7. (Original) A multi-phase combination preparation of claim 1, wherein the first phase comprises 23 or 24 initial daily dosage units and the second phase comprises 8, 7 or 6 daily dosage units, whereby the total number of daily dosage units of the first and the second phases is 30 or 31.

8. (Original) A multi-phase combination preparation of claim 1, wherein the first phase comprises 70 initial daily dosage units and the second phase comprises 14 daily dosage units.

E1 cont.

9. (Original) A multi-phase combination preparation of claim 1, wherein the first phase comprises 63 initial daily dosage units and the second phase comprises 7 daily dosage units.

10. (Previously Amended) A multi-phase combination preparation of claim 1, wherein the competitive progesterone antagonist is:

17 α -ethinyl-17 β -hydroxy-11 β -(4-methoxyphenyl)estra-4,9-dien-3-one,
11 β -(4-acetylphenyl)-17 β -hydroxy-17 α -(1-propenyl)estra-4,9-dien-3-one,
(Z)-11 β -(4-acetylphenyl)-17 β -hydroxy-17 α -(3-hydroxy-1-propenyl)estra-4,9-dien-3-one,
11 β -(4-dimethylaminophenyl)-17 β -hydroxy-17 α -(1-propenyl)estra-4,9-dien-3-one,
(Z)-9,11 α -dihydro-17 β -hydroxy-17 α -(3-hydroxy-1-propenyl)-6'-(3-pyridinyl)-4'H-naphth[3',2',1': 10,9,11]estra-4,9(11)-dien-3-one,
(Z)-11 β -[4-(dimethylamino)phenyl]-17 β -hydroxy-17 α -(3-hydroxy-1-propenyl)-estr-4-en-3-one,
4',5'-dihydro-11 β -[4-(dimethylamino)phenyl]-6 β -methylspiro[estra-4,9-dien-17 β , 2'(3'H)-furan]-3-one,
4',5'-dihydro-11 β -[4-(dimethylamino)phenyl]-7 β -methylspiro[estra-4,9-dien-17 β , 2'(3'H)-furan]-3-one, or
11 β -(4-acetylphenyl)-19,24-dinor-17,23-epoxy-17 α -chola-4,9,20-trien-3-one,
or a mixture thereof.

11. (Previously Amended) A multi-phase combination preparation of claim 1, wherein the gestagen is:

gestodene,
progesterone,
levonorgestrel,
cyproterone acetate,
chlormadinone acetate,
drospirenone (dihydrospirorenone),
norethisterone,
norethisterone acetate,
norgestimate,
desogestrel,
3-ketodesogestrel, or
dienogest,

or a mixture thereof.

12. (Original) A multi-phase combination preparation of claim 1, wherein the daily dosage of the gestagen is:

0.02-0.6 mg of levonorgestrel,
0.02-2.0 mg of cyproterone acetate,
0.01-0.3 mg of gestodene, or
0.02-0.3 mg of desogestrel,

or a bioequivalent dosage of another gestagen.

~~13.~~ (withdrawn) A multi-phase combination preparation of claim 1, wherein the gestagen gestodene is in a dosage of 0.02 to 0.075 mg.

~~14.~~ (withdrawn) A multi-phase combination preparation of claim 1, wherein the competitive progesterone antagonist (Z)-11 β -[4-(dimethylamino)phenyl]-17 β -hydroxy-17 α -(3-hydroxy-1-propenyl)estr-4-en-3-one is in a dosage of 0.01-5 mg.

15. (Currently Amended) A contraceptive kit comprising a predetermined ordered daily sequence of at least 28 individual daily dosage units comprising for administration to a patient, wherein the predetermined ordered daily sequence comprises

a first phase of at least 21 initial ~~daily~~ dosage units to be administered daily to said patient according to said predetermined order, each individual dosage unit comprising a competitive progesterone antagonist in an effective amount to inhibit ovulation during the first ~~above-named~~ phase; and followed in the ordered sequence by

a second phase of 5 to 28 separate ~~daily~~ dosage units to be administered daily to said patient, wherein each dosage unit of the second phase ~~comprising~~ comprises a gestagen,

E!cont. wherein the daily dosage units are to be taken daily by a user in the ordered sequence such that the daily units of progesterone antagonist are taken initially followed by separate administration of the daily dosage units of gestagen.

16. (Original) A contraceptive kit of claim 15, wherein the first phase comprises 21 to 27 initial daily dosage units.

17. (Original) A contraceptive kit of claim 15, wherein the first phase comprises at least 28 and at most 77 initial daily dosage units.

18. (Original) A contraceptive kit of claim 15, wherein the first phase comprises 28 initial daily dosage units.

19. (Original) A contraceptive kit of claim 15, wherein the second phase comprises 10 to 25 daily dosage units.

20. (Original) A contraceptive kit of claim 15, wherein the first phase comprises 21 initial daily dosage units and the second phase comprises 7 daily dosage units.

21. (Original) A contraceptive kit of claim 15, wherein the first phase comprises 23 or 24 initial daily dosage units and the second phase comprises 8, 7 or 6 daily dosage units, whereby the total number of daily dosage units of the first and the second phases is 30 or 31.

22. (Original) A contraceptive kit of claim 15, wherein the first phase comprises 70 initial daily dosage units and the second phase comprises 14 daily dosage units.

23. (Original) A contraceptive kit of claim 15, wherein the first phase comprises 63 initial daily dosage units and the second phase comprises 7 daily dosage units.

24. (Previously Amended) A contraceptive kit of claim 15, wherein the competitive progesterone antagonist is:

E1 cont.
17 α -ethinyl-17 β -hydroxy-11 β -(4-methoxyphenyl)estra-4,9-dien-3-one,
11 β -(4-acetylphenyl)-17 β -hydroxy-17 α -(1-propenyl)estra-4,9-dien-3-one,
(Z)-11 β -(4-acetylphenyl)-17 β -hydroxy-17 α -(3-hydroxy-1-propenyl)estra-4,9-dien-3-one,
11 β -(4-dimethylaminophenyl)-17 β -hydroxy-17 α -(1-propinyl)estra-4,9-dien-3-one,
(Z)-9,11 α -dihydro-17 β -hydroxy-17 α -(3-hydroxy-1-propenyl)-6'-(3-pyridinyl)-4'H-naphth[3',2',1': 10,9,11]estra-4,9(11)-dien-3-one,
(Z)-11 β -[4-(dimethylamino)phenyl]-17 β -hydroxy-17 α -(3-hydroxy-1-propenyl)-estr-4-en-3-one,
4',5'-dihydro-11 β -[4-(dimethylamino)phenyl]-6 β -methylspiro[estra-4,9-dien-17 β , 2'(3'H)-furan]-3-one,
4',5'-dihydro-11 β -[4-(dimethylamino)phenyl]-7 β -methylspiro[estra-4,9-dien-17 β , 2'(3'H)-furan]-3-one, or
11 β -(4-acetylphenyl)-19,24-dinor-17,23-epoxy-17 α -chola-4,9,20-trien-3-one,
or a mixture thereof.

25. (Previously Amended) A contraceptive kit of claim 15, wherein the gestagen is:
gestodene,
progesterone,
levonorgestrel,
cyproterone acetate,
chlormadinone acetate,
drospirenone (dihydrospirorenone),

norethisterone,
norethisterone acetate,
norgestimate,
desogestrel,
3-ketodesogestrel, or
dienogest,

or a mixture thereof.

E'cont.

26. (Original) A contraceptive kit of claim 15, wherein the daily dosage of the gestagen is:

0.02-0.6 mg of levonorgestrel,
0.02-2.0 mg of cyproterone acetate,
0.01-0.3 mg of gestodene, or
0.02-0.3 mg of desogestrel,

or a bioequivalent dosage of another gestagen.

~~27. (withdrawn) A contraceptive kit of claim 15, wherein the gestagen gestodene is in a dosage of 0.02 to 0.075 mg.~~

~~28. (withdrawn) A contraceptive kit of claim 15, wherein the competitive progesterone antagonist (Z)-11 β -[4-(dimethylamino)phenyl]-17 β -hydroxy-17 α -(3-hydroxy-1-propenyl)estr-4-en-3-one is in a dosage of 0.01-5 mg.~~

29. (Currently Amended) A contraceptive kit comprising a predetermined ordered daily sequence of at least 28 individual daily dosage units comprising for administration to a patient, wherein the predetermined ordered daily sequence comprises

a first phase of at least 21 separate initial daily dosage units comprising to be administered daily to said patient according to said predetermined order, each individual dosage unit comprising a competitive progesterone antagonist in an effective amount to inhibit ovulation during the first above-named phase; and followed in the ordered sequence by

a second phase of 5 to 28 separate ~~daily~~ dosage units to be administered daily to said patient, wherein each dosage unit of the second phase ~~comprising~~ comprises a gestagen, wherein the daily dosage units are to be taken daily by a user in the ordered sequence such that the daily units of progesterone antagonist are taken initially followed by separate administration of the daily dosage units of gestagen, and

El cont. ~~wherein~~ the respective dosage units are in periodically repeating subunits separated from one another spatially and/or by other markings, and

~~whereby~~ the dosage units that are present in the first phase comprise at least 21 daily dosage units in a kit, and the daily dosage units that are present in the second phase comprise at least 7 daily dosage units.

30. (Original) A contraceptive kit of claim 29, wherein the individual subunits can be separated from one another by perforations or other devices suitable for separation.

31. (Original) A contraceptive kit of claim 29, wherein the separate subunits each contain 7 dosage units.

32. (Original) A contraceptive kit of claim 29, wherein the separate subunits of the first phase each contain 7 dosage units.

~~33.~~ (Withdrawn) A method for contraception in a female mammal, comprising administering, in an at least 28-day sequential administration regimen:

a first phase of at least 21 initial daily dosage units comprising a competitive progesterone antagonist in an amount effective to inhibit ovulation during the first above-named phase, and

a second phase of 7 to 28 daily dosage units, wherein each dosage unit comprises a gestagen.

~~34.~~ (Withdrawn) A method for contraception of claim 33, wherein during the first phase, 21 to 27 initial daily dosage units are administered.

~~35.~~ (Withdrawn) A method for contraception of claim 33, wherein during the first phase, at least 28 and at most 77 initial daily dosage units are administered.

~~36.~~ (Withdrawn) A method for contraception of claim 33, wherein during the first phase, 28 initial daily dosage units are administered.

E! cont. ~~37.~~ (Withdrawn) A method for contraception of claim 33, wherein during the second phase, 7 to 14 daily dosage units are administered.

~~38.~~ (Withdrawn) A method for contraception of claim 33, wherein the first phase comprises ~~21~~ initial daily dosage units and the second phase comprises 7 daily dosage units.

~~39.~~ (Withdrawn) A method for contraception of claim 33, wherein the first phase comprises 23 or 24 initial daily dosage units and the second phase comprises 8, 7 or 6 daily dosage units, whereby the total number of daily dosage units of the first and the second phases is 30 or 31.

~~40.~~ (Withdrawn) A method for contraception of claim 33, wherein the first phase comprises 70 initial daily dosage units and the second phase comprises 14 daily dosage units.

~~41.~~ (Withdrawn) A method for contraception of claim 33, wherein the first phase comprises 63 initial daily dosage units and the second phase comprises 7 daily dosage units.

~~42.~~ (Withdrawn) A method for contraception of claim 33, wherein the competitive progesterone antagonist is selected from:

17 α -ethinyl-17 β -hydroxy-11 β -(4-methoxyphenyl)estra-4,9-dien-3-one,
11 β -(4-acetylphenyl)-17 β -hydroxy-17 α -(1-propinyl)estra-4,9-dien-3-one,
(Z)-11 β -(4-acetylphenyl)-17 β -hydroxy-17 α -(3-hydroxy-1-propenyl)estra-4, 9
dien-3-one,
11 β -(4-dimethylaminophenyl)-17 β -hydroxy-17 α -(1-propinyl)estra-4,9-dien-3
one,

(Z)-9,11 α -dihydro-17 β -hydroxy-17 α -(3-hydroxy-1-propenyl)-6'-(3-pyridinyl)4'H-naphth[3',2',1':10,9,11]estra-4,9(11)-dien-3-one,

(Z)-11 β -[4-(dimethylamino)phenyl]-17 β -hydroxy-17 α -(3-hydroxy-1-propenyl)estr-4-en-3-one,

4',5'-dihydro-11 β -[4-(dimethylamino)phenyl]-6 β -methylspiro [estra-4,9-dien17 β ,2'(3'H)-furan]-3-one,

4',5'-dihydro-11 β -[4-(dimethylamino)phenyl]-7 β -methylspiro[estra-4,9-dien17 β ,2'(3'H)-furan]-3-one, or

11 β -(4-acetylphenyl)-19,24-dinor-17,23-epoxy-17 α -chola-4,9,20-trien-3-one, or a mixture thereof.

E'cont.
~~43.~~ (Withdrawn) A method for contraception of claim 33, wherein the gestagen is selected from:

gestodene,
progesterone,
levonorgestrel,
cyproterone acetate,
chlormadinone acetate,
drospirenone (dihydrospirorenone),
norethisterone,
norethisterone acetate,
norgestimate,
desogestrel,
3-ketodesogestrel, or
dienogest,

or a mixture thereof.

~~44.~~ (Withdrawn) A method for contraception of claim 33, wherein the daily dosage of gestagen is

0.02-0.6 mg of levonorgestrel,
0.02-2.0 mg of cyproterone acetate,
0.01-0.3 mg of gestodene,

0.02-0.3 mg of desogestrel
or a bioequivalent dosage of another gestagen.

E'cont.

45. (Withdrawn) A method for contraception of claim 33, wherein the gestagen gestodene is in a dosage of 0.02 to 0.075 mg.

46. (Withdrawn) A method for contraception of claim 33, wherein the competitive progesterone antagonist (Z)-11(3-[4-(dimethylamino)phenyl]-1713-hydroxy-17a-(3hydroxy-1-propenyl)estr-4-en-3-one is in a dosage of 0.01-5 mg.

47. (cancelled)

48. (Original) A contraceptive kit of claim 30, wherein the separate subunits of the first phase each contain 7 dosage units.

49-50. (cancelled)

51. (Previously Added) The contraceptive kit of claim 31, wherein the separate subunits of the first phase each contain 7 dosage units.

52. (Previously Added) The multi-phase combination preparation of claim 1, wherein said progesterone antagonist induces amenorrhea.

53. (Currently Amended) A multi-phase combination preparation comprising a predetermined ordered daily sequence of at least 28 individual daily dosage units, comprising for administration to a patient, wherein the predetermined ordered daily sequence comprises
a first phase of at least 21 initial daily dosage units to be administered daily to said patient according to said predetermined order, each individual dosage unit comprising a
competitive progesterone antagonist, ~~wherein said progesterone antagonist is administered in~~
an amount effective to inhibit ovulation and induce amenorrhea during the first phase, and
followed in the ordered sequence by

E'cont.

a second phase of 5 to 28 separate daily dosage units to be administered daily to said patient, wherein each dosage unit of ~~this~~ the second phase ~~comprising~~ comprises a gestagen, wherein the daily dosage units are to be taken daily by a user in the ordered sequence such that the daily units of progesterone antagonist are taken initially followed by separate administration of the daily dosage units of gestagen.
